[go: up one dir, main page]

AU6773598A - Treatment of gastrointestinal disease with ppar modulators - Google Patents

Treatment of gastrointestinal disease with ppar modulators

Info

Publication number
AU6773598A
AU6773598A AU67735/98A AU6773598A AU6773598A AU 6773598 A AU6773598 A AU 6773598A AU 67735/98 A AU67735/98 A AU 67735/98A AU 6773598 A AU6773598 A AU 6773598A AU 6773598 A AU6773598 A AU 6773598A
Authority
AU
Australia
Prior art keywords
treatment
gastrointestinal disease
ppar modulators
ppar
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU67735/98A
Inventor
Johan Auwerx
Michael R Briggs
Anne-Marie Lefebvre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Ligand Pharmaceuticals Inc
Original Assignee
Institut Pasteur
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur, Ligand Pharmaceuticals Inc filed Critical Institut Pasteur
Publication of AU6773598A publication Critical patent/AU6773598A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU67735/98A 1997-03-26 1998-03-25 Treatment of gastrointestinal disease with ppar modulators Abandoned AU6773598A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4137297P 1997-03-26 1997-03-26
US60041372 1997-03-26
PCT/US1998/005852 WO1998043081A1 (en) 1997-03-26 1998-03-25 Treatment of gastrointestinal disease with ppar modulators

Publications (1)

Publication Number Publication Date
AU6773598A true AU6773598A (en) 1998-10-20

Family

ID=21916159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67735/98A Abandoned AU6773598A (en) 1997-03-26 1998-03-25 Treatment of gastrointestinal disease with ppar modulators

Country Status (2)

Country Link
AU (1) AU6773598A (en)
WO (1) WO1998043081A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
TR200202077T2 (en) * 1999-03-11 2002-11-21 Nuclear Receptor Research Limited New ligands for Prar nuclear receptors
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
ATE252091T1 (en) 1999-08-27 2003-11-15 Lilly Co Eli BIARYL-OXA(THIA)ZOL DERIVATIVES AND THEIR USE AS PPARS MODULATORS
US6159734A (en) * 2000-01-18 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of peroxisome proliferator-activated receptor gamma expression
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
ME00145B (en) 2001-01-26 2010-10-10 Merck Sharp & Dohme The use of substituted azetidinone compounds for the treatment of sitosterolemia
WO2002070011A2 (en) * 2001-02-02 2002-09-12 Smithkline Beecham Corporation Treatment of ppar mediated diseases
JPWO2002080899A1 (en) * 2001-03-30 2005-01-06 エーザイ株式会社 Gastrointestinal disease treatment
ES2272776T3 (en) 2001-09-21 2007-05-01 Schering Corporation TREATMENT OF XANTOMAS WITH DERIVATIVES OF AZETIDINONE AS INHIBITORS OF STEROL ABSORPTION.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
GB0127916D0 (en) * 2001-11-21 2002-01-16 Rowett Res Inst Method
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004016123D1 (en) 2003-03-07 2008-10-09 Schering Corp SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF HYPERCHOLESTEROLMIA
DE602004018617D1 (en) 2003-03-07 2009-02-05 Schering Corp SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF HYPERCHOLESTEROLMIA
US20080286260A1 (en) * 2004-03-26 2008-11-20 Bayer Healthcare Ag Diagnostic and Therapeutics for Diseases Associated with Peroxisome Proliferative Activated Receptor Alpha (Ppara)
ITMI20041825A1 (en) * 2004-09-24 2004-12-24 Medestea Res & Production Srl RECEPTOR AGONISTS ACTIVATING THE PROLIFERATION OF PEROXYSOMES, USEFUL IN THE PREVENTION OR TREATMENT OF GASTRITIS
ITRM20050389A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
ITRM20050390A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
RU2449999C2 (en) 2006-01-18 2012-05-10 Эвольва Са Ppar modulators
WO2008089464A1 (en) 2007-01-18 2008-07-24 Evolva Sa Prodrugs of substituted 1,3-dioxanes and their uses
WO2008089462A2 (en) 2007-01-18 2008-07-24 Evolva Sa Substituted 1,3-dioxanes and their uses
WO2008104305A1 (en) * 2007-02-27 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Pygm as a biomarker for ppara modulators
UA107562C2 (en) 2008-12-05 2015-01-26 METHOD OF TREATMENT OF PSORIASIS
CA2752626C (en) 2009-02-16 2018-03-27 Giuliani International Limited Use of ppar modulators in treating hair related conditions
JP5180978B2 (en) * 2010-02-01 2013-04-10 花王株式会社 Screening method for anti-obesity substances
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CA2864059C (en) 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
EA201491894A1 (en) 2012-04-18 2015-02-27 Ногра Фарма Лимитед METHODS OF TREATMENT OF Lactose Intolerance
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
SI3193901T1 (en) 2014-12-23 2018-06-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
SI3065748T1 (en) 2014-12-23 2018-05-31 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
SI3360559T1 (en) 2015-06-15 2020-02-28 4D Pharma Research Limited Compositions comprising bacterial strains
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
SG10201912326QA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
HRP20191949T1 (en) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3209310B1 (en) 2015-11-20 2018-01-31 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3313423B1 (en) 2016-03-04 2019-04-24 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TW201821093A (en) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 Composition comprising a bacterial strain
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
SI3630136T1 (en) 2017-05-22 2021-08-31 4D Pharma Research Limited Compositions comprising bacterial strains
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
MD3600363T2 (en) 2017-06-14 2021-05-31 4D Pharma Res Ltd Compositions comprising bacterial strains
SMT202000695T1 (en) 2017-06-14 2021-01-05 4D Pharma Res Limited Compositions comprising bacterial strains
WO2018229236A2 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
HUE070120T2 (en) 2019-02-08 2025-05-28 Nogra Pharma Ltd Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
CN112168820B (en) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 Application of SRCAP ATPase inhibitors in the treatment of colorectal cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2269897A (en) * 1992-08-13 1994-02-23 Merck Frosst Canada Inc Assay to detect peroxisome proliferator activity

Also Published As

Publication number Publication date
WO1998043081A1 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
AU6773598A (en) Treatment of gastrointestinal disease with ppar modulators
AU4050797A (en) Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU5872696A (en) Endoscope
AU7268298A (en) Differential treatment of prosthetic devices
AU3075895A (en) Endoscope
AU1450900A (en) Methods of treatment of type 2 diabetes
AU7592998A (en) Modulators of tissue regeneration
AU5899798A (en) Aminoacyl sulfamides for the treatment of hyperproliferative disorders
AU6928098A (en) Optical modulator
AU3596199A (en) Treatment of celiac disease
AU3322795A (en) Endoscope
AU1184399A (en) Therapeutic molecules
AU7058000A (en) 13 human colon and colon cancer associated proteins
AU7592398A (en) Human gp12 homolog
AU2105897A (en) Organic photoconductor and treatment therefor
AU696976B2 (en) Effluent treatment
AU8557598A (en) Treatment of fluids
AU4124497A (en) Treatment of diabetes
AUPO632997A0 (en) Diagnosis of parasites
AUPO495397A0 (en) Diagnosis of parasites
AUPO948197A0 (en) Diagnosis of parasites
AU2002302012A1 (en) Chromim/biotin treatment of type II diabetes
AUPO364796A0 (en) Diagnosis of parasites II
AU698264B3 (en) Water treatment
AU2002301764A1 (en) Treatment with anti-Erb2 antibodies